Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
News|Articles|November 2, 2001
- Pharmaceutical Technology-11-02-2001
- Volume 25
- Issue 11
Filter Integrity Testing in Liquid Applications, Revisited Part II
In the concluding part of this article, the authors address diffusive-airflow imprecisions and measurements as well as automated integrity-test equipment, variations in bubble-point measurements, and the identification of a "sterilizing" filter.
Advertisement
Articles in this issue
about 25 years ago
blankabout 25 years ago
Truth in Outsourcingabout 25 years ago
Manufacturers Face Challenges and Regulatory Changesabout 25 years ago
One-Step Aqueous Enteric Coating Systems: Scale-Up Evaluationabout 25 years ago
Outsourcing OutlookAdvertisement
Related to this article
Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
1074 Revision Needs Formulator Feedback: AAPS PharmSci 360 2026
5